Evaluating the direct effect of vaccination and non-pharmaceutical interventions during the COVID-19 pandemic in Europe.


Journal

Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676

Informations de publication

Date de publication:
11 Sep 2024
Historique:
received: 15 11 2023
accepted: 29 08 2024
medline: 12 9 2024
pubmed: 12 9 2024
entrez: 11 9 2024
Statut: epublish

Résumé

Across Europe, countries have responded to the COVID-19 pandemic with a combination of non-pharmaceutical interventions and vaccination. Evaluating the effectiveness of such interventions is of particular relevance to policy-makers. We leverage almost three years of available data across 38 European countries to evaluate the effectiveness of governmental responses in controlling the pandemic. We developed a Bayesian hierarchical model that flexibly relates daily COVID-19 incidence to past levels of vaccination and non-pharmaceutical interventions as summarised in the Stringency Index. Specifically, we use a distributed lag approach to temporally weight past intervention values, a tensor-product smooth to capture non-linearities and interactions between both types of interventions, and a hierarchical approach to parsimoniously address heterogeneity across countries. We identify a pronounced negative association between daily incidence and the strength of non-pharmaceutical interventions, along with substantial heterogeneity in effectiveness among European countries. Similarly, we observe a strong but more consistent negative association with vaccination levels. Our results show that non-linear interactions shape the effectiveness of interventions, with non-pharmaceutical interventions becoming less effective under high vaccination levels. Finally, our results indicate that the effects of interventions on daily incidence are most pronounced at a lag of 14 days after being in place. Our Bayesian hierarchical modelling approach reveals clear negative and lagged effects of non-pharmaceutical interventions and vaccination on confirmed COVID-19 cases across European countries. As soon as COVID-19 hit Europe in early 2020, non-pharmaceutical interventions such as movement restrictions and social distancing were employed to contain the pandemic. Towards the end of 2020, vaccination was available and promoted as an additional defence. We analysed almost three years of public COVID-19 data to determine how effective both types of strategies were in containing the pandemic across 38 European countries. We developed a statistical model to relate confirmed cases to how strict non-pharmaceutical interventions were and to vaccination levels. Both non-pharmaceutical interventions and vaccination resulted in decreased confirmed cases, although variation exists among countries. When an intervention is applied, the effect on number of confirmed cases could be seen most about fourteen days after implementation.

Sections du résumé

BACKGROUND BACKGROUND
Across Europe, countries have responded to the COVID-19 pandemic with a combination of non-pharmaceutical interventions and vaccination. Evaluating the effectiveness of such interventions is of particular relevance to policy-makers.
METHODS METHODS
We leverage almost three years of available data across 38 European countries to evaluate the effectiveness of governmental responses in controlling the pandemic. We developed a Bayesian hierarchical model that flexibly relates daily COVID-19 incidence to past levels of vaccination and non-pharmaceutical interventions as summarised in the Stringency Index. Specifically, we use a distributed lag approach to temporally weight past intervention values, a tensor-product smooth to capture non-linearities and interactions between both types of interventions, and a hierarchical approach to parsimoniously address heterogeneity across countries.
RESULTS RESULTS
We identify a pronounced negative association between daily incidence and the strength of non-pharmaceutical interventions, along with substantial heterogeneity in effectiveness among European countries. Similarly, we observe a strong but more consistent negative association with vaccination levels. Our results show that non-linear interactions shape the effectiveness of interventions, with non-pharmaceutical interventions becoming less effective under high vaccination levels. Finally, our results indicate that the effects of interventions on daily incidence are most pronounced at a lag of 14 days after being in place.
CONCLUSIONS CONCLUSIONS
Our Bayesian hierarchical modelling approach reveals clear negative and lagged effects of non-pharmaceutical interventions and vaccination on confirmed COVID-19 cases across European countries.
As soon as COVID-19 hit Europe in early 2020, non-pharmaceutical interventions such as movement restrictions and social distancing were employed to contain the pandemic. Towards the end of 2020, vaccination was available and promoted as an additional defence. We analysed almost three years of public COVID-19 data to determine how effective both types of strategies were in containing the pandemic across 38 European countries. We developed a statistical model to relate confirmed cases to how strict non-pharmaceutical interventions were and to vaccination levels. Both non-pharmaceutical interventions and vaccination resulted in decreased confirmed cases, although variation exists among countries. When an intervention is applied, the effect on number of confirmed cases could be seen most about fourteen days after implementation.

Autres résumés

Type: plain-language-summary (eng)
As soon as COVID-19 hit Europe in early 2020, non-pharmaceutical interventions such as movement restrictions and social distancing were employed to contain the pandemic. Towards the end of 2020, vaccination was available and promoted as an additional defence. We analysed almost three years of public COVID-19 data to determine how effective both types of strategies were in containing the pandemic across 38 European countries. We developed a statistical model to relate confirmed cases to how strict non-pharmaceutical interventions were and to vaccination levels. Both non-pharmaceutical interventions and vaccination resulted in decreased confirmed cases, although variation exists among countries. When an intervention is applied, the effect on number of confirmed cases could be seen most about fourteen days after implementation.

Identifiants

pubmed: 39261675
doi: 10.1038/s43856-024-00600-0
pii: 10.1038/s43856-024-00600-0
doi:

Types de publication

Journal Article

Langues

eng

Pagination

178

Subventions

Organisme : Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders)
ID : 11E3222N
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 101003688
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 101003688
Organisme : Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders)
ID : G0A4121N

Informations de copyright

© 2024. The Author(s).

Références

Hens, N., Vranck, P. & Molenberghs, G. The COVID-19 epidemic, its mortality, and the role of non-pharmaceutical interventions. Eur. Heart J. Acute Cardiovasc. Care 9, 204–208 (2020).
pubmed: 32352314 doi: 10.1177/2048872620924922
Ferguson, N. et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand (Imperial College COVID-19 Response Team, 2020).
Mathieu, E. et al. A global database of COVID-19 vaccinations. Nat. Hum. Behav. 5, 947–953 (2021).
pubmed: 33972767 doi: 10.1038/s41562-021-01122-8
Hale, T. et al. A global panel database of pandemic policies (Oxford COVID-19 government response tracker). Nat. Hum. Behav. 5, 529–538 (2021).
pubmed: 33686204 doi: 10.1038/s41562-021-01079-8
Flaxman, S. et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584, 257–261 (2020).
pubmed: 32512579 doi: 10.1038/s41586-020-2405-7
Banholzer, N. et al. The methodologies to assess the effectiveness of non-pharmaceutical interventions during COVID-19: a systematic review. Eur. J. Epidemiol. 37, 1003–1024 (2022).
pubmed: 36152133 pmcid: 9510554 doi: 10.1007/s10654-022-00908-y
Perra, N. Non-pharmaceutical interventions during the COVID-19 pandemic: a review. Phys. Rep. 913, 1–52 (2021).
pubmed: 33612922 pmcid: 7881715 doi: 10.1016/j.physrep.2021.02.001
Talic, S. et al. Effectiveness of public health measures in reducing the incidence of COVID-19, SARS-CoV-2 transmission, and COVID-19 mortality: systematic review and meta-analysis. BMJ 375, e068302 (2021).
Mendez-Brito, A., Bcheraoui, C. E. & Pozo-Martin, F. Systematic review of empirical studies comparing the effectiveness of non-pharmaceutical interventions against COVID-19. J. Infect. 83, 281–293 (2021).
pubmed: 34161818 pmcid: 8214911 doi: 10.1016/j.jinf.2021.06.018
Eikenberry, S. E. et al. To mask or not to mask: modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. Infect. Dis. Model. 5, 293–308 (2020).
pubmed: 32355904 pmcid: 7186508
Mendes, J. M. & Coelho, P. S. The effect of non-pharmaceutical interventions on COVID-19 outcomes: a heterogeneous age-related generalisation of the SEIR model. Infect. Dis. Model. 8, 742–768 (2023).
pubmed: 37366483 pmcid: 10287188
Santos, J. V. et al. Factors associated with non-pharmaceutical interventions compliance during COVID-19 pandemic: a Portuguese cross-sectional survey. J. Public Health 45, 47–56 (2023).
doi: 10.1093/pubmed/fdac001
Neyens, T. et al. Can COVID-19 symptoms as reported in a large-scale online survey be used to optimise spatial predictions of COVID-19 incidence risk in Belgium? Spat. Spatiotemporal Epidemiol. 35, 100379 (2020).
pubmed: 33138946 pmcid: 7518805 doi: 10.1016/j.sste.2020.100379
Downing, S. T., Mccarty, R. J., Guastello, A. D., Cooke, D. L. & Mcnamara, J. P. Assessing the predictors of adaptive and maladaptive COVID-19 preventive behaviours: an application of protection motivation theory. Psychol., Health Med. 28, 460–474 (2023).
pubmed: 35769017 doi: 10.1080/13548506.2022.2093925
Brauner, J. M. et al. Inferring the effectiveness of government interventions against COVID-19. Science 371, eabd9338 (2021).
pubmed: 33323424 doi: 10.1126/science.abd9338
Liu, Y. et al. The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. BMC Med. 19, 1–12 (2021).
doi: 10.1186/s12916-020-01872-8
Ge, Y. et al. Impacts of worldwide individual non-pharmaceutical interventions on COVID-19 transmission across waves and space. Int. J. Appl. Earth Obs. Geoinf. 106, 102649 (2022).
pubmed: 35110979 pmcid: 8666325
Haug, N. et al. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat. Hum. Behav. 4, 1303–1312 (2020).
pubmed: 33199859 doi: 10.1038/s41562-020-01009-0
Sharma, M. et al. Understanding the effectiveness of government interventions against the resurgence of COVID-19 in Europe. Nat. Commun. 12, 5820 (2021).
pubmed: 34611158 pmcid: 8492703 doi: 10.1038/s41467-021-26013-4
Campbell, F. et al. Increased transmissibility and global spread of SARSCoV-2 variants of concern as at June 2021. Eurosurveillance 26, 1–6 (2021).
doi: 10.2807/1560-7917.ES.2021.26.24.2100509
Gozzi, N., Bajardi, P. & Perra, N. The importance of non-pharmaceutical interventions during the COVID-19 vaccine rollout. PLOS Comput. Biol. 17, e1009346 (2021).
pubmed: 34506478 pmcid: 8457458 doi: 10.1371/journal.pcbi.1009346
Ge, Y. et al. Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories. Nat. Commun. 13, 3106 (2022).
pubmed: 35661759 pmcid: 9166696 doi: 10.1038/s41467-022-30897-1
Lionello, L. et al. Non-pharmaceutical interventions in response to the COVID-19 pandemic in 30 European countries: the ECDC–JRC response measures database. Eurosurveillance 27, 2101190 (2022).
pubmed: 36239171 pmcid: 9562809 doi: 10.2807/1560-7917.ES.2022.27.41.2101190
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246 doi: 10.1056/NEJMoa2034577
Moghadas, S. M. et al. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLOS Biol. 19, 1–13 (2021).
doi: 10.1371/journal.pbio.3001211
Almon, S. The distributed lag between capital appropriations and expenditures. Econometrica 33, 178–196 (1965).
doi: 10.2307/1911894
Schwartz, J. The distributed lag between air pollution and daily deaths. Epidemiology 11, 320–326 (2000).
pubmed: 10784251 doi: 10.1097/00001648-200005000-00016
Nottmeyer, L. et al. The association of COVID-19 incidence with temperature, humidity, and UV radiation—a global multi-city analysis. Sci. Total Environ. 854, 158636 (2023).
pubmed: 36087670 doi: 10.1016/j.scitotenv.2022.158636
Rasmussen, C. E. & Williams, C. K. I. Gaussian processes for machine learning (MIT Press, 2006).
Heaton, M. J. & Peng, R. D. Flexible distributed lag models using random functions with application to estimating mortality displacement from heat-related deaths. J. Agric. Biol., Environ. Stat. 17, 313–331 (2012).
pubmed: 23125520 doi: 10.1007/s13253-012-0097-7
Abrahamsen, P. A Review of Gaussian Random Fields and Correlation Functions (Norsk Regnesentral/Norwegian Computing Center, 1997).
Monod, M. et al. Regularised B-splines projected Gaussian process priors to estimate time-trends in age-specific COVID-19 deaths. Bayesian Anal. 18, 957 – 987 (2023).
doi: 10.1214/22-BA1334
Lewandowski, D., Kurowicka, D. & Joe, H. Generating random correlation matrices based on vines and extended onion method. J. Multivar. Anal. 100, 1989–2001 (2009).
doi: 10.1016/j.jmva.2009.04.008
Gabry, J. & Češnovar, R. cmdstanr: R interface to ’cmdstan’ (2022).
Team, R. C. R: A language and environment for statistical computing https://www.R-project.org/ (2022).
Carpenter, B. et al. Stan: a probabilistic programming language. J. Stat. Softw., Artic. 76, 1–32 (2017).
Kay, M. Tidybayes: Tidy Data and Geoms for Bayesian Models http://mjskay.github.io/tidybayes/ (2022).
Vehtari, A., Gelman, A., Simpson, D., Carpenter, B. & Burkner, P. C. Rank-normalization, folding, and localization: An improved R-hat for assessing convergence of MCMC (with discussion). Bayesian Anal. 16, 667–718 (2021).
doi: 10.1214/20-BA1221
Fajgenblat, M. et al. Code for: Evaluating the direct effect of vaccination and non-pharmaceutical interventions during the COVID-19 pandemic in Europe. Zenodo https://doi.org/10.5281/zenodo.13292978 (2024).
Du, Z. et al. Pandemic fatigue impedes mitigation of COVID-19 in Hong Kong. in Proc. of the National Academy of Sciences of the United States of America. 119, (2022).
Petherick, A. et al. A worldwide assessment of changes in adherence to COVID-19 protective behaviours and hypothesized pandemic fatigue. Nat. Hum. Behav. 5, 1145–1160 (2021).
pubmed: 34345009 doi: 10.1038/s41562-021-01181-x
Yan, Y. et al. Measuring voluntary and policy-induced social distancing behavior during the COVID-19 pandemic. in Proc. of the National Academy of Sciences, (2021).
Fontanet, A. & Cauchemez, S. COVID-19 herd immunity: where are we? Nat. Rev. Immunol. 20, 583–584 (2020).
pubmed: 32908300 pmcid: 7480627 doi: 10.1038/s41577-020-00451-5
Andrews, N. et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022).
pubmed: 35249272 doi: 10.1056/NEJMoa2119451
Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679+ (2022).
pubmed: 35042229 pmcid: 8942855 doi: 10.1038/s41586-022-04411-y
Andersson, N. W. et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged less than 50 years in Nordic countries: nationwide cohort study. BMJ 382, e075286 (2023).
Matrajt, L., Eaton, J., Leung, T. & Brown, E. R. Vaccine optimization for COVID-19: Who to vaccinate first? Sci. Adv. 7, eabf1374 (2021).
pubmed: 33536223 pmcid: 8128110 doi: 10.1126/sciadv.abf1374
Lau, H. et al. Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters. Pulmonology 27, 110–115 (2021).
pubmed: 32540223 doi: 10.1016/j.pulmoe.2020.05.015
Albani, V., Loria, J., Massad, E. & Zubelli, J. COVID-19 underreporting and its impact on vaccination strategies. BMC Infect. Dis. 21, 1–13 (2021).
doi: 10.1186/s12879-021-06780-7
Mathieu, E. et al. Coronavirus pandemic (COVID-19). Our World in Data https://ourworldindata.org/coronavirus (2020).
Kirpich, A. et al. Excess mortality in Belarus during the COVID-19 pandemic as the case study of a country with limited non-pharmaceutical interventions and limited reporting. Sci. Rep. 12, 5475 (2022).
pubmed: 35361826 pmcid: 8970068 doi: 10.1038/s41598-022-09345-z
Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757–773 (2021).
pubmed: 34535792 pmcid: 8447121 doi: 10.1038/s41576-021-00408-x
Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409–424 (2021).
pubmed: 34075212 pmcid: 8167834 doi: 10.1038/s41579-021-00573-0
Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055 (2021).
pubmed: 33658326 pmcid: 8128288 doi: 10.1126/science.abg3055
Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924–944 (2022).
pubmed: 35202601 pmcid: 8863502 doi: 10.1016/S0140-6736(22)00152-0
Levin, E. G. et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).
pubmed: 34614326 doi: 10.1056/NEJMoa2114583

Auteurs

Maxime Fajgenblat (M)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute (DSI), UHasselt, Hasselt, Belgium. maxime.fajgenblat@gmail.com.
Laboratory of Freshwater Ecology, Evolution and Conservation, KU Leuven, Leuven, Belgium. maxime.fajgenblat@gmail.com.

Geert Molenberghs (G)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute (DSI), UHasselt, Hasselt, Belgium.
Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), KU Leuven, Leuven, Belgium.

Johan Verbeeck (J)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute (DSI), UHasselt, Hasselt, Belgium.

Lander Willem (L)

Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.

Jonas Crèvecoeur (J)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute (DSI), UHasselt, Hasselt, Belgium.
Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), KU Leuven, Leuven, Belgium.

Christel Faes (C)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute (DSI), UHasselt, Hasselt, Belgium.

Niel Hens (N)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute (DSI), UHasselt, Hasselt, Belgium.
Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.

Patrick Deboosere (P)

Interface Demography (ID), Department of Sociology, Vrije Universiteit Brussel, Brussels, Belgium.

Geert Verbeke (G)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute (DSI), UHasselt, Hasselt, Belgium.
Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), KU Leuven, Leuven, Belgium.

Thomas Neyens (T)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute (DSI), UHasselt, Hasselt, Belgium.
Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), KU Leuven, Leuven, Belgium.

Classifications MeSH